The abstract is read at the publisher; the summary is JClub's.
A CD9-targeted tetrahedral DNA nanostructure delivering chemically modified siRNA silences human IGHE in humanized IgE/FcεRI double-transgenic mice, with a single 3-day intranasal course lasting one week.
- Why it matters: Allergic rhinitis is driven by hIgE, yet current treatments lack precision and standard models often miss human-specific immune interactions.
- What they did: The team optimized siRNA chemistry to siRNA3a (phosphorothioate, 2'-O-methyl, 2'-fluoro) and administered CD9-TDN-siRNA intranasally for 3 days in a humanized IgE/FcεRI double-transgenic mouse model, measuring nasal symptom scores and systemic hIgE suppression.
- The result: The nanostructures penetrated nasal mucus and entered target cells via CD9-mediated endocytosis, producing durable hIgE silencing that persisted for one week and significantly outperformed traditional corticosteroids in durability and specificity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.